



Biotech Daily

Friday August 7, 2015

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: PHARMAXIS UP 2%, AVITA DOWN 12.5%**
- * **CLARITY, MELBOURNE UNI \$365k ARC IMAGING GRANT**
- * **GENERA 6,000 PATIENT DATA 'CONSISTENT' WITH 2011 STUDY**
- * **FIL TAKES 6% OF IMPEDIMED**
- * **HUNTER HALL TAKES 14.7% OF GI DYNAMICS**
- * **UBS AG BUYS, SELLS, BORROWS, RETURNS ACRUX SHARES TO 7.5%**

MARKET REPORT

The Australian stock market lost 2.41 percent on Friday August 7, 2015 with the ASX200 down 135.3 points to 5,474.8 points.

Just five of the Biotech Daily Top 40 stocks were up, 21 fell, 13 traded unchanged and one was untraded. All three Big Caps fell.

Pharmaxis was the best, up 0.5 cents or 2.4 percent to 21.5 cents with 662,698 shares traded. Mesoblast and Universal Biosensors were up more than one percent; with Acrux and Medical Developments up by less than one percent.

Avita led the falls, down one cent or 12.5 percent to seven cents with 64,850 shares traded.

Orthocell lost 6.5 percent; Clinuvel and Polynovo fell more than five percent; Actinogen, Living Cell, Neuren and Oncosil fell more than four percent; Antisense, Biotron and Genetic Technologies were down three percent or more; Admedus, Benitec, Cellmid, Ellex and Prima shed more than two percent; Cochlear, CSL, Nanosonics, Resmed and Tissue Therapies were down more than one percent; with Impedimed, Sirtex and Viralytics down by less than one percent.

CLARITY PHARMACEUTICALS, UNIVERSITY OF MELBOURNE

Clarity says that with the University of Melbourne it has been awarded a \$365,000 three-year Australian Research Council grant for novel diagnostic imaging research.

Clarity said that the grant would fund the development of new agents for diagnostic imaging using positron emission tomography (PET).

The company said that the aim of the research was to improve clinical results for patients including the molecular imaging of the brain for various disorders, "where PET imaging has exquisite image quality".

Clarity said the grant would fund research into the use of PET isotopes of copper, gallium and fluorine with a view to replacing existing technologies that rely on single-photon emission from technetium and the technique of single photon emission computed tomography.

The company said that the ARC Linkage Grant was co-awarded to Prof Paul Donnell at the University of Melbourne's Department of Chemistry and Bio21 Institute.

Clarity said that Prof Donnelly had expertise in the application of coordination chemistry to metal-based drugs and the study of metal ions in biological systems and was the inventor of several patents for radiopharmaceutical technologies.

Clarity said it had licenced from the University of Melbourne two patents from Prof Donnelly's portfolio, stemming from a previous ARC Linkage Grant between Clarity and the University of Melbourne between 2012 and 2014.

The company said that the licences covered analogues of the sarcophagine chelators and complemented its own patent family, which were being used for the imaging of cancer in a current clinical trial.

Clarity chief executive officer Dr Matthew Harris said that "grants like ARC Linkage are vital for supporting innovation in Australia and enhance the industry competitiveness on the global arena".

Clarity is a private company.

GENERA BIOSYSTEMS

Genera says data from the 'Predictors 3' trial of its Papttype human papillomavirus test was "consistent with prior data generated by Papttype in the Predictors 2 study".

Genera did not disclose the results from the 6,000 patient Predictors 3 study in a cervical cancer screening population from London's Wolfson Institute of Preventive Medicine but said the Predictors 2 study showed the Papttype test "was comparable to other high sensitivity tests for detecting [cervical intraepithelial neoplasia2+ (CIN2+) with] approximately 95 percent sensitivity, whilst being capable of delivering additional information and substantially higher specificity when applying a diagnostic classification of oncogenic [human papillomavirus] genotypes by sequentially maximising positive predictive values".

Last month, Genera said that the 'Predictors 3' study of its Papttype human papillomavirus (HPV) diagnostic was completed in May 2015 at the Wolfson Institute (BD: Jul 17, 2015).

Today, the company said the data was in summary form, but was consistent with the data in the 1,099-patient Predictors 2 study (BD: Nov 2, 2011).

Genera said it intended to share the Predictors 3 data under confidentiality with its prospective partners.

The company said that the study was independently undertaken by the Wolfson Institute and supported by Cancer Research UK Programme grants, so full public disclosure would be made when it was published in a journal later in the year.

Genera was unchanged at 33 cents.

IMPEDIMED

The Singapore-based FIL Limited says it has increased its substantial shareholding in Impedimed from 14,748,056 shares (5.04%) to 18,112,316 shares (6.18%).

FIL, formerly Fidelity Investments Limited, said it bought and sold shares between December 15, 2014 and August 4, 2015, buying shares in the rights issue at 60 cents and trading shares at prices between 75 cents and \$1.19.

Impedimed fell one cent or 0.8 percent to \$1.18.

GI DYNAMICS

Hunter Hall Investment Management says it has increased its substantial shareholding in GI Dynamics from 63,984,375 shares (13.49%) to 69,779,090 shares (14.71%).

The Sydney-based Hunter Hall said that from July 17 to August 4, 2015 it bought and sold shares acquired the shares in 12 transactions, most recently buying 4,677,142 shares for \$187,553 of four cents a share.

On July 30, GI Dynamics told the market that it had closed its pivotal US trial of the Endobarrier due to serious adverse events (BD: Jul 30, 2015).

Following a teleconference on July 31, GI Dynamics fell as much as 9.4 cents or 69.6 percent to 4.1 cents, before closing down 9.3 cents or 68.9 percent at 4.2 cents with 5.6 million shares traded, falling to 3.7 cents on August 4 and 5 (BD: Jul 31, 2015).

GI Dynamics was up 0.3 cents or 7.9 percent to 4.1 cents.

ACRUX

The Singapore-based UBS AG and related bodies corporate have increased their holding in Acrux from 10,771,754 shares (6.47%) to 12,493,473 shares (7.50%).

UBS AG said that on August 3 and 4, 2015, in more than 80 mainly very small trades, it bought, sold, borrowed and returned shares for institutions, including Citibank, Citigroup, JP Morgan Chase Bank, Macquarie Bank, Morgan Stanley, the Northern Trust Company, Brown Brothers Harriman, BMO Capital Markets Corp and State Street Bank & Trust Co. UBS AG has previously said that the shares were held for Warbont Nominees and various custodians and were held with the "power to control disposal over shares pursuant to stock borrowing and lending activities" (BD: Dec 19, 2012; Nov 21, 2013).

Acrux has been reported as one of the most heavily 'short-sold' stocks in the Australian biotechnology sector.

Acrux was up half a cent or 0.8 percent to 66.5 cents.